Literature DB >> 17527051

Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.

Keishi Makino1, Hideo Nakamura, Mareina Kudo, Hideo Takeshima, Jun-Ichi Kuratsu.   

Abstract

An 80-year-old woman presented with primary central nervous system (CNS) lymphoma manifesting as progressive disorientation and loss of activity. She received three cycles of high-dose methotrexate. The tumor shrank after two cycles and her mental status improved, but she suffered tumor recurrence. The second-line treatment consisted of four cycles of rituximab but the tumor enlarged. She was then treated with three cycles of temozolomide. Magnetic resonance imaging revealed no evidence of disease. Her mental status and performance status improved, and she suffered no toxicity. She is able to pursue her daily life without recurrence after 16 cycles of temozolomide. Temozolomide may be effective against relapsed primary CNS lymphoma without causing neurotoxicity in the elderly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17527051     DOI: 10.2176/nmc.47.229

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  2 in total

1.  Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Authors:  Keishi Makino; Hideo Nakamura; Taku-Ichiro Hide; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

2.  O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Authors:  Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jennifer A Quinn; Alan D Austin; James E Herndon; Roger E McLendon; Henry S Friedman
Journal:  J Neurooncol       Date:  2013-05-18       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.